Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Zepzelca’s pivotal surprise
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
